Inmune Bio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Inmune Bio Inc (INMB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Inmune Bio Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 207,222M combined for tracked competitors (0.0% combined share).
- Scale: Inmune Bio Inc ranks #120 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
- Peer differentiation: Revenue per employee of $0.02M compares with $1.41M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Inmune Bio Inc vs. its Competitors, Q2 2026
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Inmune Bio Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Inmune Bio Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Inmune Bio Inc's competitor groups requires a Commercial License.
Inmune Bio Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Inmune Bio Inc | - | - | - | - |
| Competitors combined (18) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
INMB Stock Performance relative to its Competitors
INMB Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Immunitybio inc | 282.9% | Outperformed |
| 3 | Cullinan Therapeutics Inc | 282.9% | Outperformed |
| 4 | Quince Therapeutics Inc | 282.9% | Outperformed |
| 5 | Eli Lilly And Company | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Inmune Bio Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Inmune Bio Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Inmune Bio Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Inmune Bio Inc | 53.44 | 0.36 |
| Eli Lilly And Company | 1,058,837.89 | 79,665.80 |
| Abbvie Inc | 471,581.88 | 64,386.00 |
| Amgen Inc | 227,462.72 | 38,095.00 |
| Regeneron Pharmaceuticals Inc | 79,738.50 | 15,534.70 |
| Moderna Inc | 78,517.44 | 2,228.00 |
| SUBTOTAL | 1,971,574.91 | 207,232.86 |
Sign in to see all competitors of Inmune Bio Inc .
Sources: Inmune Bio Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Inmune Bio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Inmune Bio Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| infliximab | Named by the company | 85% |
| etanercept | Named by the company | 85% |
| INKmune | Named by the company | 85% |
| INB03 | Named by the company | 85% |
| adalimumab | Named by the company | 85% |
| Medicines Co | Named by the company | 85% |
| Denali Therapeutics Inc | Named by the company | 85% |
| Immunitybio inc | Named by the company | 85% |
| Abbvie Inc | Named by the company | 85% |
| Alector Inc | Named by the company | 85% |
| Novabridge Biosciences | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Inmune Bio Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Inmune Bio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Neurocrine Biosciences Inc | Reportable 100.00 % |
| Immunitybio inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Inmune Bio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Inmune Bio Inc | 53 | 16,952 | -876,952 |
| Eli Lilly And Company | 1,058,838 | 1,593,316 | 534,224 |
| Abbvie Inc | 471,582 | 1,129,579 | 110,807 |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| Regeneron Pharmaceuticals Inc | 79,739 | 1,008,092 | 280,902 |
| Moderna Inc | 78,517 | 474,043 | -670,426 |
| PEERS TOTAL | 1,971,521 | 1,414,711 | 297,232 |
Inmune Bio Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Exelixis Inc | United States 91.44 % |
| Immunitybio inc | United States 98.99 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Inmune Bio Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Inmune Bio Inc's industry classification, broader than the peer set above. Market cap in millions of $.Inmune Bio Inc ranks #120 of 159 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,331, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 226,707 | 26.02 % |
| 2 | Gilead Sciences Inc | 185,928 | 21.34 % |
| 3 | Moderna Inc | 76,517 | 8.78 % |
| 4 | Argenx Se | 63,326 | 7.27 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 120 | Inmune Bio Inc | 52 | 0.01 % |
Market cap and industry share for the rest of Inmune Bio Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Inmune Bio Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 115 | Champions Oncology Inc | 68 | -23.16 % |
| 116 | Leonabio Inc | 66 | -26.51 % |
| 117 | Scilex Holding Company | 64 | 45.89 % |
| 118 | Mink Therapeutics Inc | 61 | -15.06 % |
| 119 | Aligos Therapeutics Inc | 1,234 | 12.3% |
| 120 | Inmune Bio Inc | 52 | -3.45 % |
| 121 | Exozymes Inc | 1,234 | 12.3% |
| 122 | Xtant Medical Holdings Inc | 1,234 | 12.3% |
| 123 | Instil Bio Inc | 1,234 | 12.3% |
| 124 | Tscan Therapeutics Inc | 1,234 | 12.3% |
| 125 | Metagenomi Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Inmune Bio Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Inmune Bio Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | 1.9x | 5.1x | -3.2x |
| Return on Equity | -82.87 % | industry aggregate | -79.44 % |
| Return on Invested Capital | -44.83 % | -6.17 % (avg) | -38.66 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Inmune Bio Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - |
| Operating Margin | - | - | - | -6,938.77 % | - | - |
| Return on Invested Capital | -15.78 % | -19.67 % | -19.59 % | -17.48 % | -62.39 % | -87.60 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Inmune Bio Inc's BCG Growth-Share Matrix
Relative market share (vs Inmune Bio Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Inmune Bio Inc falls in the Question Mark quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 10.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Inmune Bio Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,331 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Inmune Bio Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Inmune Bio Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Inmune Bio Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Inmune Bio Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Inmune Bio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 79.4 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Inmune Bio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Inmune Bio Inc | 1.94 | 3.96 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Inmune Bio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Inmune Bio Inc | Q2 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| PEERS TOTAL | +24.2 % | +60.4 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Inmune Bio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Inmune Bio Inc | Q2 2026 | - | -39.1 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
Inmune Bio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Inmune Bio Inc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| Moderna Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Inmune Bio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Inmune Bio Inc | - | 150.10 |
| Eli Lilly And Company | 39.77 | 13.29 |
| Abbvie Inc | 75.22 | 7.32 |
| Amgen Inc | 25.97 | 5.97 |
| Regeneron Pharmaceuticals Inc | 18.63 | 5.13 |
| Moderna Inc | - | 35.24 |
| PEERS AVERAGE | 45.30 | 9.51 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.